Select a Region
North America

Browsing Archive: Scientific InsightsScientific Insights | EVERSANA - Part 3

EVERSANA
Posted on 9월 20, 20239/20/23

An umbrella review of the surgical performance of Harmonic ultrasonic devices and impact on patient outcomes

EVERSANA
Posted on 9월 20, 20239/20/23

Healthcare Resource Utilization and Costs Among Overweight and Obese Users of a Digital Weight Loss Intervention Compared to Non-Users:A Retrospective Analysis.

EVERSANA
Posted on 9월 20, 20239/20/23

Letter in Reply: indirect comparison of quality-of-life scores between patients with advanced breast cancer receiving palbociclib and abemaciclib in combination with fulvestrant

EVERSANA
Posted on 2월 1, 20232/1/23

Efficacy classification of modern therapies in multiple sclerosis

EVERSANA
Posted on 2월 1, 20232/1/23

Matching-adjusted indirect comparison of palbociclib versus ribociclib and abemaciclib in hormone receptor-positive/HER2-negative advanced breast cancer

EVERSANA
Posted on 2월 1, 20232/1/23

CDK4/6 inhibitors in HR+/HER2- advanced/metastatic breast cancer: a systematic literature review of real-world evidence studies

EVERSANA
Posted on 2월 1, 20232/1/23

Risk of recurrence among patients with HR-positive, HER2-negative, early breast cancer receiving adjuvant endocrine therapy: A systematic review and meta-analysis

EVERSANA
Posted on 2월 1, 20232/1/23

Matching-adjusted indirect treatment comparison of siponimod and other disease modifying treatments in secondary progressive multiple sclerosis

EVERSANA
Posted on 2월 1, 20232/1/23

The importance of considering differences in study and patient characteristics before undertaking indirect treatment comparisons: a case study of siponimod for secondary progressive multiple sclerosis

EVERSANA
Posted on 2월 1, 20232/1/23

The impact of clinical heterogeneity on conducting network meta-analyses in transthyretin amyloidosis with polyneuropathy

Scientific Insights